Stock Events

Stock Events

Exscientia 

0
0
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Schwab U.S. Broad Market
SCHB
Mkt Cap0
Schrodinger is a direct competitor in the computational drug discovery space, offering similar software solutions for molecular simulations.
Royalty Pharma
RPRX
Mkt Cap29.91B
Royalty Pharma invests in and funds pharmaceutical and biotech companies, potentially competing for investment in similar drug discovery projects as Exscientia.
Atomera
ATOM
Mkt Cap183.8M
Atomwise uses artificial intelligence for drug discovery, directly competing with Exscientia's AI-driven drug development approach.
Evogene
EVGN
Mkt Cap6.72M
Evogene applies computational biology to discover and develop drugs, making it a competitor in the AI-driven drug discovery market.
CRISPR Therapeutics
CRSP
Mkt Cap4.97B
CRISPR Therapeutics is focused on gene editing, a different but competing approach to developing treatments that could overlap with Exscientia's target disease areas.
Editas Medicine
EDIT
Mkt Cap410.06M
Editas Medicine is another gene editing company, competing in the space of developing novel therapeutics which may overlap with Exscientia's interests.
Intellia Therapeutics
NTLA
Mkt Cap1.75B
Intellia Therapeutics is involved in CRISPR/Cas9 gene editing, competing in the innovative therapeutic development space.
Beam Therapeutics
BEAM
Mkt Cap2.81B
Beam Therapeutics focuses on precision genetic medicines, competing in the advanced therapy medicinal products space that could intersect with Exscientia's work.
Twist Bioscience
TWST
Mkt Cap10.13B
Twist Bioscience operates in the synthetic biology space, providing tools and technologies that could compete with Exscientia's drug discovery platform.

About

Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy. It is also involved in the development of EXS4318, a PKC-theta inhibitor, under Phase 1 clinical trial for inflammation and immunology indications; EXS74539, a LSD1 inhibitor, under preclinical studies for SCLC, AML, and potential additional indications; EXS73565, a MALT1 inhibitor, under preclinical studies for multiple hematology indications; and DSP-0038, currently in Phase 1 studies. The company has collaboration agreements with Merck KGaA, Bristol Myers Squibb, Sanofi, Bill & Melinda Gates Foundation, Charité " Universitätsmedizin Berlin, Rallybio, and GT Apeiron Therapeutics. Exscientia plc was founded in 2012 and is headquartered in Oxford, the United Kingdom.
Show More
CEO
Dr. David Hallett Ph.D.
Employees
483
Country
United States
ISIN
US30223G1022
WKN
000A3C4QW

Listings

MU
DE
0RK.MU
STU
DE
0RK.STU

0 Comments

Share your thoughts

FAQs

What is Exscientia stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange Exscientia stocks are traded under the ticker 0RK.MU.
How many employees does Exscientia have?▼
As of November 2, 2026, the company has 483 employees.
In which sector is Exscientia located?▼
Exscientia operates in the Health & Wellness sector.
When did Exscientia complete a stock split?▼
Exscientia has not had any recent stock splits.
Where is Exscientia headquartered?▼
Exscientia is headquartered in Oxford, United States.